Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Preferred Stock Liabilities (2018 - 2019)

Black Diamond Therapeutics (BDTX) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $200.6 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $200.6 million, compared with a TTM value of $200.6 million through Dec 2019, changed N/A, and an annual FY2019 reading of $200.6 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $200.6 million for Q4 2019 at Black Diamond Therapeutics, up from $115.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $200.6 million in Q4 2019 and bottomed at $60.8 million in Q1 2019.